CardiacSense

Company Overview

Snapshot

Founded in December 2009 by Eldad Shemesh, CardiacSense operates with 11–50 employees. The company has raised a total of $24.43 million across 9 funding rounds from 7 investors.

Business overview

CardiacSense specializes in developing and commercializing a medical-grade smartwatch designed for long-term, continuous monitoring of heart arrhythmias, such as atrial fibrillation or cardiac arrest, and blood pressure. The company's core technology leverages advanced optics, mechanics, and signal processing, backed by a strong intellectual property portfolio, to provide highly accurate vital sign monitoring. Serving the healthcare industry, CardiacSense operates within the Health Tech & Life Sciences sector, focusing on digital healthcare, patient remote monitoring, and medical devices, with applications in cardiology for patients, hospitals, and clinics.

Strategic signal

In January 2023, CardiacSense received FDA clearance for its medical-grade watch. This regulatory approval is a significant validation of the device's accuracy and safety, opening up the crucial US market for the company and signaling a major step towards broader commercial adoption and market penetration for its continuous heart arrhythmia and blood pressure monitoring technology.

Company Intelligence Q&A

What regulatory milestone did CardiacSense achieve in 2023?

In January 2023, CardiacSense received FDA clearance for its medical-grade watch, enabling its use for continuous monitoring of heart arrhythmias and blood pressure in the United States.

What significant international distribution agreement did CardiacSense sign in 2020?

In September 2020, CardiacSense signed an exclusive distribution agreement in Switzerland. Additionally, in June 2020, the company signed a $32.4 million deal for its medical monitoring watch in India.

What was a notable application of CardiacSense's technology in 2021?

In May 2021, CardiacSense's medical watch was selected to remotely monitor the vital signs and general medical condition of Israeli astronauts in space.

When did CardiacSense receive CE Mark approval for its medical watch?

In February 2021, CardiacSense's medical-grade watch received CE Mark approval for the continuous detection of atrial fibrillation.